Vaccine against Streptococcus suis Infection in Pig Based on Alternative Carrier Protein Conjugate

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00027162%3A_____%2F22%3AN0000132" target="_blank" >RIV/00027162:_____/22:N0000132 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/62156489:43210/22:43922327 RIV/00216224:14310/22:00128096 RIV/61988987:17110/22:A2302H1T

Výsledek na webu

<a href="https://www.mdpi.com/2076-393X/10/10/1620" target="_blank" >https://www.mdpi.com/2076-393X/10/10/1620</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/vaccines10101620" target="_blank" >10.3390/vaccines10101620</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Vaccine against Streptococcus suis Infection in Pig Based on Alternative Carrier Protein Conjugate

Popis výsledku v původním jazyce

Streptococcus suis is a serious pathogen in the pig industry with zoonotic potential. With respect to the current effort to reduce antibiotic use in animals, a prophylactic measure is needed to control the disease burden. Unfortunately, immunization against streptococcal pathogens is challenging due to nature of the interaction between the pathogen and the host immune system, but vaccines based on conjugates of capsular polysaccharide (CPS) and carrier protein were proved to be efficient. The main obstacle of these vaccines is manufacturing cost, limiting their use in animals. In this work, we tested an experimental vaccine against Streptococcus suis serotype 2 based on capsular polysaccharide conjugated to chicken ovalbumin (OVA) and compared its immunogenicity and protectivity with a vaccine based on CRM197 conjugate. Ovalbumin was selected as a cheap alternative to recombinant carrier proteins widely used in vaccines for human use. We found that the ovalbumin-based experimental vaccine successfully induced immune response in pigs, and the IgG antibody response was even higher than after immunization with capsular polysaccharide CRM197 conjugate. Protectivity of vaccination against infection was evaluated in the challenge experiment and was found promising for both conjugates.

Název v anglickém jazyce

Vaccine against Streptococcus suis Infection in Pig Based on Alternative Carrier Protein Conjugate

Popis výsledku anglicky

Streptococcus suis is a serious pathogen in the pig industry with zoonotic potential. With respect to the current effort to reduce antibiotic use in animals, a prophylactic measure is needed to control the disease burden. Unfortunately, immunization against streptococcal pathogens is challenging due to nature of the interaction between the pathogen and the host immune system, but vaccines based on conjugates of capsular polysaccharide (CPS) and carrier protein were proved to be efficient. The main obstacle of these vaccines is manufacturing cost, limiting their use in animals. In this work, we tested an experimental vaccine against Streptococcus suis serotype 2 based on capsular polysaccharide conjugated to chicken ovalbumin (OVA) and compared its immunogenicity and protectivity with a vaccine based on CRM197 conjugate. Ovalbumin was selected as a cheap alternative to recombinant carrier proteins widely used in vaccines for human use. We found that the ovalbumin-based experimental vaccine successfully induced immune response in pigs, and the IgG antibody response was even higher than after immunization with capsular polysaccharide CRM197 conjugate. Protectivity of vaccination against infection was evaluated in the challenge experiment and was found promising for both conjugates.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

40301 - Veterinary science

Projekt

<a href="/cs/project/QK1810193" target="_blank" >QK1810193: Moderní metody diagnostiky, terapie a prevence infekcí Streptococcus suis jako nástroj pro sestavování cílených kontrolních programů v chovech prasat</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Vaccines

ISSN

2076-393X

e-ISSN

2076-393X

Svazek periodika

10

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

18

Strana od-do

"1620"

Kód UT WoS článku

000873669400001

EID výsledku v databázi Scopus

2-s2.0-85140801371